New drugs for the treatment of metastatic colorectal cancer

doi:10.4251/wjgo.v13.i11.1551

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4653)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

257

WORD

HTML

2540

Figures (1-1)

238

Tables (1-1)

287

Sum=3406

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

426

Download

821

Sum=1247

Nov 15, 2021 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1551-1560
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1551

New drugs for the treatment of metastatic colorectal cancer

Sara Cherri, Michela Libertini, Alberto Zaniboni

Sara Cherri, Michela Libertini, Alberto Zaniboni, Department of Oncology, Fondazione Poliambulanza, Brescia 25124, Italy

Author contributions: Cherri S and Libertini M drafted the manuscript; Zaniboni A revised this manuscript; All the authors approved the final version.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Sara Cherri, MD, Medical Assistant, Department of Oncology, Fondazione Poliambulanza, Via L. Bissolati 57, Brescia 25124, Italy. sara.cherri@poliambulanza.it

Received: April 2, 2021
Peer-review started: April 2, 2021
First decision: June 23, 2021
Revised: July 1, 2021
Accepted: September 8, 2021
Article in press: September 8, 2021
Published online: November 15, 2021
Processing time: 223 Days and 17.2 Hours

Core Tip

Core Tip: Although metastatic colorectal cancer (CRC) is a relevant oncological issue, few drugs have changed clinical practice in the last decade. In fact, there are many difficulties in the development of new drugs closely related to the biology of CRC; however, improved knowledge of the molecular biology of this cancer has led to a few steps forward and the hope for more targeted cancer treatments for metastatic CRC patients in the near future.